160P COLUMBIA-1: A phase Ib/II, open-label, randomized, multicenter study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab as first-line (1L) therapy in metastatic microsatellite-stable colorectal cancer (MSS-mCRC)

Autor:	N.H. Segal, J. Tie, S. Kopetz, M.P. Ducreux, E. Chen, R. Dienstmann, A. Hollebecque, M. Reilley, M.E. Elez Fernandez, J. Cosaert, J. Cain, M. Hernandez, N. Hewson, Z.A. Cooper, M. Dressman, J. Tabernero
Rok vydání:	2022
Předmět:	Oncology Immunology and Allergy
Zdroj:	Immuno-Oncology and Technology. 16:100272
ISSN:	2590-0188
DOI:	10.1016/j.iotech.2022.100272
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::03ad663214c20173159525fc5be1be04 https://doi.org/10.1016/j.iotech.2022.100272 Zobrazit plný text záznamu